Vicore Pharma: Funding, Investors & Team (Sep 2026)
Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
Vicore Pharma has raised $46.0M across 1 funding round on record, the most recent an undisclosed round of $46.0M announced in Jun 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Vicore Pharma Company Profile and Key Stats
Latest funding round on record: Jun 2023.
Vicore Pharma Funding Rounds
Vicore Pharma Founders and Leadership Team
Contact details for the Vicore Pharma team: 1 of 1 has an email address on file.
Start 14-day free trial →Vicore Pharma Funding Compared to Other Biotechnology Startups
Vicore Pharma's latest round of $46.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Vicore Pharma in Biotechnology and Mölndal
Companies Similar to Vicore Pharma
Pixelgen Technologies, established in Sweden in 2020, focuses on the advancement of biomedical research and…
Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic…
Emulsi Biotech is a biotechnology company that develops lipid technology to deliver biologic drugs orally.
Our vision is to develop and bring to the market safe and effective treatments for women specific diseases…
OncoZenge is a Swedish pharmaceutical company. It develops better products for the supportive care of cancer…
Elicera Therapeutics is a clinical stage immuno-oncology company developing cell and gene therapies for…
Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for…
Moleculent is dedicated to creating tech-based products that utilize fresh knowledge about the molecular…
Bio-Works was established in 2006 and specializes in creating, producing, and distributing cutting-edge…
Verigraft AB is a biotech company that creates personalized tissue-engineered transplants for use in…
Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic…
ArgusEye is a biotech firm that offers sensor solutions for instant identification of biological systems and…
Vicore Pharma Funding FAQs
What does Vicore Pharma do?
Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
How much funding has Vicore Pharma raised?
Vicore Pharma has raised $46.0M across 1 round on record. The most recent is an undisclosed round of $46.0M announced in Jun 2023.
When did Vicore Pharma last raise funding?
Vicore Pharma's most recent funding round on record is an undisclosed round of $46.0M, announced in Jun 2023.
Who founded Vicore Pharma?
FundedIQ lists Mikael Nygard (Founder) at Vicore Pharma.
Where is Vicore Pharma headquartered?
Vicore Pharma is based in Mölndal, Vastra Gotaland, Sweden.
How many employees does Vicore Pharma have?
Vicore Pharma is in the 11-50 employee band.
How does Vicore Pharma's funding compare to other Biotechnology startups?
Vicore Pharma's latest round of $46.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Vicore Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Vicore Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.